Safety and efficacy of bilastine: a new H₁-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria

Bibliography

• Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-98
   PubMed Web of Science ®Google Scholar
• Bilastine SPC 2010. Summary of Product Characteristics for Bilastine 20 mg. Available from: https://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFichaWordPdf&codigo=73027&formato=pdf&formulario=FICHAS [Last accessed 2 April 2011]
   Google Scholar
• Emanuel MB. Histamine and the antiallergic antihistamines: a history of their discoveries. Clin Exp Allergy 1999;29(Suppl 3):1-11
   PubMedGoogle Scholar
• Nicholson AN. Central effects of H1 and H2 antihistamines. Aviat Space Environ Med 1985;56:293-8
   PubMed Web of Science ®Google Scholar
• Meltzer EO. Comparative safety of H1 antihistamines. Ann Allergy 1991;67:625-33
   PubMedGoogle Scholar
• Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351:2203-17
   PubMed Web of Science ®Google Scholar
• Holgate ST, Canonica GW, Simons FE, Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003;33:1305-24
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76
   PubMed Web of Science ®Google Scholar
• Jauregizar N, de la Fuente L, Lucero ML, Pharmacokinetic-pharmacodynamic modelling of the antihistaminic H1-effect of bilastine. Clin Pharmacokinet 2009;48:543-54
   PubMed Web of Science ®Google Scholar
• Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy 2010;65(Suppl 93):1-13
   Web of Science ®Google Scholar
• Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol 2010;70:645-55
   PubMed Web of Science ®Google Scholar
• Alejandro A, Lucero ML, Sainz L, Orjales A. Gastrointestinal metabolism of bilastine. In vitro study. XIII Congreso Nacional de la Sociedad Espanola de Quimica Terapeutica. Santiago de Compostela (Spain). 9 – 12 September 2003; Abstract P-74. Congress Abstracts Book.2003:130
   Google Scholar
• FAES FARMA S. A. June 2011. Available from: http://www.faes.es/faesfarma.lasso?LANG=en&FA=def90a960e136d7d [Last accessed 15 June 2011]
   Google Scholar
• Sologuren A, Lucero ML, Valiente R, Human mass balance with [14C]-bilastine following oral administration to healthy volunteers. Basic Clin Pharmacol Toxicol 2009;105(Suppl 1):106-7
   Google Scholar
• Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57
   PubMed Web of Science ®Google Scholar
• Zechnich AD, Hedges JR, Eiselt-Proteau D, Haxby D. Possible interactions with terfenadine or astemizole. West J Med 1994;160:321-5
   PubMedGoogle Scholar
• Crean CS, Sologren A, Valiente R, McLaverty D. The drug-drug interaction of ketoconazole on bilastine pharmacokinetics. Basic Clin Pharmacol Toxicol 2007;101(Suppl 1):148-9
   Google Scholar
• Takano M, Hasegawa R, Fukuda T, Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in caco-2 cells. Eur J Pharmacol 1998;358:289-94
   PubMed Web of Science ®Google Scholar
• Corcostegui R, Labeaga L, Innerarity A, Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005;6:371-84
   PubMedGoogle Scholar
• Wolff S C, Brubaker K, Navratil T, Evaluation of muscarinic receptor antagonism by antihistamines. Allergy 2007;62(Suppl 83):138
   Google Scholar
• Garcia-Gea C, Martinez-Colomer J, Antonijoan RM, Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008;28:675-85
   PubMed Web of Science ®Google Scholar
• Corcostegui R, Labeaga L, Innerarity A, In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 2006;7:219-31
   PubMedGoogle Scholar
• Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010;59:391-8
   PubMed Web of Science ®Google Scholar
• Bachert C, Kuna P, Sanquer F, Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64:158-65
   PubMed Web of Science ®Google Scholar
• Kuna P, Bachert C, Nowacki Z, Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39:1338-47
   PubMed Web of Science ®Google Scholar
• Sologuren A, Valiente R, Crean C, McLaverty D. Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10 mg cetirizine. J Clin Pharmacol 2007;47:1198
   Web of Science ®Google Scholar
• Zuberbier T, Oanta A, Bogacka E, Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65:516-28
   PubMed Web of Science ®Google Scholar
• Tashiro M, Kato M, Miyake M, Dose dependency of brain histamine H1 receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [(11)C]doxepin. Hum Psychopharmacol 2009;24:540-8
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:617-26
   PubMed Web of Science ®Google Scholar
• Howarth PH, Stern MA, Roi L, Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:927-33
   PubMed Web of Science ®Google Scholar
• Salmun LM, Gates D, Scharf M, Loratadine versus cetirizine: assessment of somnolence and motivation during the workday. Clin Ther 2000;22:573-82
   PubMed Web of Science ®Google Scholar
• Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ 2000;320:1184-6
   PubMed Web of Science ®Google Scholar
• Tashiro M, Sakurada Y, Iwabuchi K, Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004;44:890-900
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002;32:133-9
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24
   PubMed Web of Science ®Google Scholar
• Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999;36:179-94
   PubMed Web of Science ®Google Scholar
• Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003;31:312-18
   PubMed Web of Science ®Google Scholar
• Cvetkovic M, Leake B, Fromm MF, OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27:866-71
   PubMed Web of Science ®Google Scholar
• Obradovic T, Dobson GG, Shingaki T, Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm Res 2007;24:318-27
   PubMed Web of Science ®Google Scholar
• Burton PS, Crean C, Kagey M, Nielsen JW. Permeability characteristics of bilastine, a potent and selective H1 receptor antagonist, in caco-2 cells. AAPS J 2007;9(Suppl 2):2910
   Google Scholar
• Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001;46:27-43
   PubMed Web of Science ®Google Scholar
• Petri N, Tannergren C, Rungstad D, Lennernas H. Transport characteristics of fexofenadine in the caco-2 cell model. Pharm Res 2004;21:1398-404
   PubMed Web of Science ®Google Scholar
• Gonzalo A, Lucero ML. Identification of processes involved in bilastine bioavailability in rats. Drug Metab Rev 2008;40(Suppl 1):42-3
   Google Scholar
• Morag N, Lucero ML, Orjales A. In vitro hepatic metabolism of [14C] bilastine. Drug Metab Rev 2007;39(Suppl 1):114
   Google Scholar
• Richardson GS, Roehrs TA, Rosenthal L, Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002;22:511-15
   PubMed Web of Science ®Google Scholar
• Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004;92:294-303
   PubMed Web of Science ®Google Scholar
• Garcia-Gea C, Clos S, Antonioli DA, Crossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinical trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects. Basic Clin Pharmacol Toxicol 2006;99(Suppl 1):30
   Google Scholar
• Conen S, Theunissen EL, Van Oers AC, Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2010; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Craft TM. Torsade de pointes after astemizole overdose. Br Med J (Clin Res Ed) 1986;292:660
   PubMed Web of Science ®Google Scholar
• Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6
   PubMed Web of Science ®Google Scholar
• Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996;36:233-52
   PubMed Web of Science ®Google Scholar
• Polak S, Wisniowska B, Brandys J. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. J Appl Toxicol 2009;29:183-206
   PubMed Web of Science ®Google Scholar
• Taglialatela M, Pannaccione A, Castaldo P, Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998;54:113-21
   PubMed Web of Science ®Google Scholar
• Tyl B, Kabbaj M, Azzam S, Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol June 3 2011; DOI:10.1177/0091270011407191
   PubMed Web of Science ®Google Scholar
• ICH Harmonized Tripartite Guideline E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/Step4/E14_Guideline.pdf [Last accessed 2 April 2011]
   Google Scholar
• Malik M, Hnatkova K, Schmidt A, Smetana P. Electrocardiographic QTc changes due to moxifloxacin infusion. J Clin Pharmacol 2009;49:674-83
   PubMed Web of Science ®Google Scholar
• Takemasa H, Nagatomo T, Abe H, Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br J Pharmacol 2008;153:439-47
   PubMed Web of Science ®Google Scholar
• Montoro J, del Cuvillo A, Jauregui I, Bilastine and the central nervous system: incidence of somnolence [abstract 926]. XXX Congress of the European Academy of Allergology and Clinical Immunology. Istanbul (Turkey). Jun 11 – 15, 2011. Allergy 2011;66(Suppl 94):358
   Google Scholar
• Maurer M, Weller K, Bindslev-Jensen C, Unmet clinical needs in chronic spontaneous urticaria. A GA(2) LEN task force report. Allergy 2011;66:317-30
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427-43
   PubMed Web of Science ®Google Scholar